MorphoSys has posted a net profit of EUR2.7m for the second quarter 2010 compared to net profit of EUR1.5m for the comparable period in 2009. Operating profit was EUR3.6m, compared to EUR2.4m for the comparable period in 2009.
Revenue for six months ended June 30, 2010, is EUR43.5m compared to EUR37.9m for the year ago period. Operating profit was EUR8.3m, compared to EUR6.6m for the year ago period.
MorphoSys has posted a net profit of EUR6m compared to EUR5m for the year ago period.
Simon Moroney, CEO of MorphoSys, said: “Our therapeutic antibody pipeline continues to expand and mature. By in-licensing Phase 1 antibody from Xencor, we took a step in the execution of our plan to build a portfolio of proprietary therapeutic antibodies to complement those being developed by our partners.
“Our cash-flow is enabling us to drive a proprietary research and development effort. We’re on track to achieving the goals we set ourselves at the beginning of the year, in both the therapeutic and AbD Serotec business segments.”